Market Research Logo
Publisher: FirstWord
Category: Healthcare

Healthcare market research reports by FirstWord

(73 reports matching your criteria)
  • Duchenne Muscular Dystrophy: KOL Insight [2018]

    ... known cure and few treatment options. Since 2014, two antisense oligonucleotide therapies [Exondys 51 (Sarepta Therapeutics) and Translarna (PTC Therapeutics)] have been approved but how are they faring on the market? Find out how key ... Read More

  • Digital Therapeutics: Taking Digital Health to a New Level

    ... therapeutics (DTx) are now part of the health delivery landscape. They hold the promise of augmenting or replacing therapies and may show utility in improving patient adherence and in key areas of unmet need such ... Read More

  • Paying for Digital Health: Payer Insights

    ... records and telemedicine to emerging technologies such as smart pills/inhalers and 3D dose printing. Great stuff, but payers are only interested in value. Where there is evidence that digital technology delivers lower costs by minimising ... Read More

  • Medical Affairs Reputations (US) [Growth Hormone Deficiency]

    ... growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, and the United Kingdom) are doing a passable job, they may be letting doctors down in other ways. From not valuing doctors’ time enough ... Read More

  • Medical Affairs Reputations (EU5) [CLL]

    ... haematologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be ... Read More

  • Medical Affairs Reputations (EU5) [Growth Hormone Deficiency]

    ... growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, and the United Kingdom) are doing a passable job, they may be letting doctors down in other ways. From not valuing doctors’ time enough ... Read More

  • MSL stakeholder engagement- meeting expectations

    ... page… The executive summary, taken directly from the report, presents key findings from the research Research objectives and methodologies employed to produce the report Detailed report contents Why this report is important to you 1. ... Read More

  • Charting MSL Activity and Performance (2017)

    ... (MSL) professionals in the US and EU5 which reveals the changing face of MSL activity and the key engagement strategies and performance metrics that are being employed today. Building on the ground breaking 2015 Survey, ... Read More

  • How Payers Want to Work With Pharma

    ... approach to payer negotiations getting your message across? Too often pharma fails to provide the data and contracting innovation that will unlock the door to a deal. It can be better. Report Overview In How ... Read More

  • Medical Affairs Reputations (US) [RCC]

    ... our survey of 100 medical oncologists. As part of list of suggested improvements, they identified at least 4 ways that teams for major renal cell carcinoma (RCC) treatments could do a better job of providing ... Read More

  • Medical Affairs Reputations (EU5) [RCC]

    ... our survey of 150 medical oncologists. As part of list of suggested improvements, they identified at least 5 ways that teams for major renal cell carcinoma (RCC) treatments could do a better job of providing ... Read More

  • Pulling the Data Puzzle Together: Being Payer-Centric

    ... prove; who should be told? From the all-important payer perspective, the ‘data puzzle’ is a complex one to solve. Payers want to see data on safety, efficacy, effectiveness, affordability and patient population - but in ... Read More

  • Medical Affairs Reputations (EU5) [NSCLC]

    ... may be time to step things up. Our survey of 150 medical oncologists shows that they’re hungry for information, and feel that EU5-based medical affairs teams for leading NSCLC treatments should be contacting them more ... Read More

  • Medical Affairs Reputations (US) [NSCLC]

    ... may be time to step things up. Our survey of 150 medical oncologists shows that they’re hungry for information, and feel that EU5-based medical affairs teams for leading NSCLC treatments should be contacting them more ... Read More

  • Medical Affairs Reputations (EU5) [PsO]

    ... are running neck and neck with at least one rival. The 150 dermatologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put ... Read More

  • Medical Affairs Reputations (US) [PsO]

    ... are running neck and neck with at least one rival. The 100 dermatologists we polled say that each of those teams needs improvement in at least one specific area, but are those targeted improvements enough ... Read More

  • NPS+ (US) [RCC]

    ... the Renal Cell Carcinoma (RCC) market in the US? Are oncologists satisfied with what’s available? And how well are key messages on safety, cost and risk profile getting through? A ‘must read’ for marketers and ... Read More

  • NPS+ (EU5) [RCC]

    ... Net Promoter Scores all have high numbers of oncologists who are ‘passive’ about the brand. Is there a significant opportunity for drug marketing and market access teams to sway opinion with the right messaging? A ... Read More

  • The Future of Medical Affairs

    ... And demands are set to grow with a wider number of stakeholders needing ever more specific data, information and support. How will medical affairs professionals meet evolving stakeholder expectations and prove to colleagues the critical ... Read More

  • The Healthcare Internet of Things: A Network of Opportunities for All (2016)

    ... Now our sector and others are seeing people and technology come together in incredibly exciting new ways, creating stronger connections and enabling continuous and productive conversations to take place in real time. The opportunities for ... Read More

  • The Real Value of Medical Affairs

    ... interactions would elevate MA to that elusive next level of engagement? Ultimately, what makes doctors want to talk to Medical Science Liaisons (MSLs)? The Real Value of Medical Affairs covers both sides of the equation ... Read More

  • What is Value in Healthcare: The payer definition

    ... view or wider health savings? With no consensus on the definition of value, how can industry meet the expectations of diverse and often sceptical US and European payers to secure market access? Informed by expert ... Read More

  • Patient Assistance Programs

    ... sceptical, seeing PAPs as a cynical ploy by Pharma to buy market share and support drug prices. This report explores the patient benefits, operational challenges and attitudes to, and the future for, PAPs through the ... Read More

  • MAR T2DM (US)

    ... (T2DM) market. Are they delivering the services doctors need most, or are they simply more active than the rest of the pack? Find out, and see how your team measures up, in Medical Affairs Reputations: ... Read More

  • Digital Health Start Ups

    ... of 10 digital health startups and presents a checklist of where Pharma should get involved and the developments it must watch. Based on primary research with leading proponents of digital health, the report is essential ... Read More

< prev 1 3

Research Assistance

Healthcare market research reports by FirstWord

Join Alert Me Now!

Sign Up

Find out more on our blog